Nutrition in CAPD: Serum bicarbonate and the ubiquitin-proteasome system in muscle

Kidney International

Volumn 61, Issue 4, 2002, Pages 1286-1292

  Pickering, Warren P ^a,b   Russ Price, S ^a,b   Bircher, Gemma ^a,b   Marinovic, Anne C ^a,b   Mitch, William E ^a,b   Walls, John ^a,b  

^a LEICESTER GENERAL HOSPITAL   (United Kingdom)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acidosis; Branched chain amino acids; Chronic renal failure; Diet and dialysis; Protein degradation

Indexed keywords

AMINO ACID; BICARBONATE; LACTIC ACID; MESSENGER RNA; PROTEASOME; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; BODY MASS; BODY WEIGHT; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DEGRADATION; DIALYSATE; HUMAN; MALE; MUSCLE BIOPSY; MUSCLE LEVEL; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; VASTUS LATERALIS MUSCLE;

EID: 0036223212     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2002.00276.x     Document Type: Article

References (52)

1. Adaptation to low-protein diets in renal failure: Leucine turnover and nitrogen balance
2. Long-term adaptive responses to dietary protein restriction in chronic renal failure
3. Factors predicting malnutrition in hemodialysis patients: A cross-sectional study
4. Nutritional aspects of peritoneal dialysis
5. Nutrition and adequacy of dialysis: How do hemodialysis and CAPD compare?
6. Protein metabolism in patients with chronic renal failure: Role of uremia and dialysis
7. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of the death rate differences among facilities
8. Biological basis of hypoalbuminemia in ESRD
9. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients
10. Metabolic acidosis and uremic toxicity: Protein and amino acid metabolism
11. Metabolic acidosis and skeletal muscle adaptation to low protein diets in chronic uremia
12. The alkaline treatment of chronic nephritis
13. Alkali therapy versus sodium chloride supplement in low birthweight infants with incipient late metabolic acidosis
14. Attainment of normal stature with alkali therapy in infants and children with classic renal tubular acidosis
15. The effect of the correction of metabolic acidosis on nitrogen and protein balance of patients with chronic renal failure
16. Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation
17. Correction of acidosis in hemodialysis decreases whole-body protein degradation
18. Correction of acidosis in CAPD decreases whole body protein degradation
19. Role of an improvement in acid-base status and nutrition in CAPD patients
20. Skeletal muscle degradation and nitrogen wasting in rats with chronic metabolic acidosis
21. Glucocorticoids and acidosis stimulate protein and amino acid catabolism in vivo
22. Mechanisms for defects in muscle protein metabolism in rats with chronic uremia: The influence of metabolic acidosis
23. Acidosis, not azotemia, stimulates branched-chain amino acid catabolism in uremic rats
24. The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent, ubiquitin-proteasome pathway
25. Mechanisms of muscle wasting: The role of the ubiquitin-proteasome system
26. Branched-chain amino acid metabolism in rat muscle: Abnormal regulation in acidosis
27. Rat muscle branched-chain ketoacid dehydrogenase activity and mRNAs increase with extracellular acidemia
28. Conchotome and needle percutaneous biopsy of skeletal muscle
29. Acidosis and glucocorticoids concomitantly increase ubiquitin and proteasome subunit mRNAs in rat muscle
30. Skeletal muscle protein synthesis and degradation in patients with chronic renal failure
31. Nutrition and chronic renal failure in rats: What is an optimal dietary protein?
32. Pattern of noncompliance with dialysis exchanges in peritoneal dialysis patients
33. Kidney, splanchnic, and leg protein turnover in humans: Insights from leucine and phenylalanine kinetics
34. ++-activated and ATP-ubiquitin-dependent proteolytic pathways in skeletal muscle from head trauma patients
35. Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle
36. Contribution of the ubiquitin-proteasome pathway to overall muscle proteolysis in hypercatabolic patients
37. Increased muscle ubiquitin mRNA levels in gastric cancer patients
38. Metabolic acidosis stimulates muscle protein degradation by activating the ATP-dependent pathway involving ubiquitin and proteasomes
39. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting
40. Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats is regulated by glucocorticoids
41. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting
42. Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome pathway by a mechanism including gene transcription
43. Insulin resistance in uremia
44. Glucose intolerance following chronic metabolic acidosis in man
45. Plasma levels of IL-1B, TNF-α and their specific inhibitors in undialyzed chonic renal failure, CAPD, and hemodialysis patients
46. Mechanisms of malnutrition in uremia
47. Infusion of tumor necrosis factor/cachetin promotes muscle catabolism in the rat: A synergistic effect with interleukin 1
48. Administration of endotoxin, tumor necrosis factor, or interleukin 1 to rats activates skeletal muscle branched-chain alpha-keto acid dehydrogenase
49. TNF directly stimulates glucose uptake and leucine oxidation and inhibits FFA flux in conscious dogs
50. Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NF-κB
51. Transcription factors and muscle cachexia: Have we defined a therapeutic target?
52. Identification, purification, and characterization of a high molecular weight, ATP-dependent activator (PA700) of the 20S proteasome